Güzel Özge, Kehoe Patrick G
Cerebrovascular and Dementia Research Group, Bristol Medical School, University of Bristol, Bristol, UK.
Department of Genetics and Bioengineering, Alanya Alaaddin Keykubat University, Antalya, Türkiye.
Curr Top Behav Neurosci. 2025;69:107-127. doi: 10.1007/7854_2024_525.
The renin-angiotensin system (RAS) is becoming increasingly recognised as a biochemical pathway relevant to the development and progression of Alzheimer's disease (AD). RAS involvement in AD was initially linked to AD via numerous genetic association studies and more recent Genome-Wide Association Studies (GWAS), and in some cases in relation to classical hallmarks of AD pathology. Since these initial findings, which will be summarised here, several complementary areas of research are converging in support of what has been proposed as the Angiotensin Hypothesis for Alzheimer's disease. This hypothesis proposes how the RAS and disease-associated changes to the normal balance between opposing regulatory pathways within RAS warrant careful consideration in the pathogenesis of AD and its pathology. We discuss some of these in relation to RAS-targeting therapeutics, originally developed for the treatment of cardiovascular conditions, and how they might be repurposed as interventions for AD.
肾素-血管紧张素系统（RAS）越来越被认为是一条与阿尔茨海默病（AD）的发生和发展相关的生化途径。RAS与AD的关联最初是通过众多基因关联研究以及最近的全基因组关联研究（GWAS）建立的，在某些情况下还与AD病理学的经典特征有关。自从这些最初的发现（将在此处进行总结）以来，几个互补的研究领域正在汇聚，以支持被提出的阿尔茨海默病血管紧张素假说。该假说提出了RAS以及RAS内相反调节途径之间正常平衡的疾病相关变化如何在AD的发病机制及其病理学中值得仔细考虑。我们将讨论其中一些与最初为治疗心血管疾病而开发的RAS靶向疗法有关的内容，以及它们如何可能被重新用作AD的干预措施。
